帕拉米韦治疗儿童流行性感冒的循证药物经济学评价

黄光亮; 闫宇驰; 何文娟; 赵晓娟; 赵永红; 刘秀菊

doi:10.13407/ j.cnki.jpp.1672-108X.2022.02.003

您当前的位置：

首页 >

文章列表页 >

帕拉米韦治疗儿童流行性感冒的循证药物经济学评价

论著 | 更新时间：2022-11-03

- 帕拉米韦治疗儿童流行性感冒的循证药物经济学评价
- Evidence-Based Pharmacoeconomic Evaluation of Peramivir in the Treatment of Influenza in Children
- 儿科药学杂志 2022年28卷第2期页码：8-11
- 作者机构：
  
  1. 河北医科大学第二医院,石家庄,050000
  2. 南方医科大学,广州,510515
- 作者简介：
- 基金信息：
  
  基金项目:河北省医学科学研究课题计划项目,编号20200978。
- DOI：10.13407/ j.cnki.jpp.1672-108X.2022.02.003
  中图分类号：
- 纸质出版日期：2022，
  
  网络出版日期：2022-2-10，
扫描看全文
黄光亮, 闫宇驰, 何文娟, 等. 帕拉米韦治疗儿童流行性感冒的循证药物经济学评价[J]. 儿科药学杂志, 2022,28(2):8-11.

Huang Guangliang, Yan Yuchi, He Wenjuan, et al. Evidence-Based Pharmacoeconomic Evaluation of Peramivir in the Treatment of Influenza in Children[J]. 2022,28(2):8-11.
黄光亮, 闫宇驰, 何文娟, 等. 帕拉米韦治疗儿童流行性感冒的循证药物经济学评价[J]. 儿科药学杂志, 2022,28(2):8-11. DOI： 10.13407/ j.cnki.jpp.1672-108X.2022.02.003.

Huang Guangliang, Yan Yuchi, He Wenjuan, et al. Evidence-Based Pharmacoeconomic Evaluation of Peramivir in the Treatment of Influenza in Children[J]. 2022,28(2):8-11. DOI： 10.13407/ j.cnki.jpp.1672-108X.2022.02.003.

摘要

目的：探讨静脉滴注帕拉米韦相较于口服奥司他韦在治疗儿童流行性感冒的有效性、安全性和经济性。方法：计算机检索中国知网、中国生物医学文献数据库、维普、万方数据库、PubMed、the Cochrane Library、Web of Science等中英文数据库。根据纳入标准和排除标准，筛选符合要求的帕拉米韦对比奥司他韦治疗儿童流行性感冒的随机对照试验，文献质量评价根据Cochrane协作网提供的质量评估标准进行，终点观测指标由RevMan 5.4软件进行Meta分析，使用成本-效果分析法对所得结果进行经济学评价。结果：临床有效率和不良事件发生率两组比较差异均有统计学意义（RR=1.11，95% CI 1.07~1.15，Z=5.14，P<0.000 01；RR=0.66，95% CI 0.47~0.94，P=0.02）。在经济学方面，以帕拉米韦用药时间和不同儿童体质量分别组合得出不同的ICER值，帕拉米韦单次用药的增量成本效益比（ICER）值分别为体质量≤15 kg，ICER=3.81；体质量>15~23 kg，ICER=5.72；体质量>23~40 kg，ICER=1.15；体质量>40 kg，ICER=-3.41。结论：在治疗儿童流行性感冒的过程中，帕拉米韦相比于奥司他韦在有效率和不良事件发生率上均占有优势；在经济学方面，奥司他韦普遍占有优势，帕拉米韦仅在单次用药时具有成本-效果比。

Abstract

Objective: To probe into the differences for efficacy

safety and economy of intravenous peramivir and oral oseltamivir in the treatment of influenza in children. Methods: CNKI

CBM

VIP

Wanfang

PubMed

the Cochrane Library and Web of Science database were retrieved. According to the inclusion and exclusion criteria

the eligible randomized controlled trials of peramivir versus oseltamivir in the treatment of influenza in children were screened. Literature quality was evaluated according to the quality assessment criteria provided by the Cochrane system evaluation standard. The endpoint observation indicators were obtained by Meta analysis with RevMan 5.4 software

and the results were evaluated economically by cost-effectiveness analysis. Results: There were significant differences between two groups in clinical effective rate and incidence of adverse events (RR=1.11

95%CI from 1.07 to 1.15

Z=5.14

P<0.000

01; RR=0.66

95%CI from 0.47 to 0.94

P=0.02). In terms of economics

different incremental cost-effectiveness ratio (ICER) values were derived by combining the duration of paramivir dosing and different body mass in children

respectively. The ICER values for single dose of peramivir were body mass ≤15 kg

ICER=3.81; body mass >15 to 23 kg

ICER=5.72; body mass >23 to 40 kg

ICER=1.15; body mass >40 kg

ICER=-3.41. Conclusion: Compared with oseltamivir

peramivir has advantages in the effective rate and incidence of adverse events in the treatment of influenza in children; in terms of economics

oseltamivir generally held an advantage

with paramivir having a cost-effectiveness ratio advantage only at single dose.

关键词

帕拉米韦奥司他韦儿童流行性感冒Meta分析循证药物经济学

Keywords

peramiviroseltamivirchildrennfluenzaMeta analysisevidence-based pharmacoeconomics

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

某三甲综合医院36 例儿童药物误服中毒病例分析及药学服务思考

右美托咪定与氢吗啡酮复合滴鼻在腺样体手术患儿术前母婴分离镇静中的应用

西罗莫司治疗儿童蓝色橡皮疱痣综合征5 例并文献复习

唑来膦酸用于儿童代谢性骨疾病有效性和安全性的系统评价

基于加权逼近理想解排序法的儿童患者注射用伏立康唑的药物利用评价